This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
Clinical Summary

Psoriasis: real-world data supports efficacy of secukinumab

Takeaway

  • Secukinumab is associated with clinical benefit in patients with moderate to severe plaque psoriasis, according to results from the real-world PROSPECT study.

Why this matters

  • Cohort included prior and concurrent users of other systemic therapy.

Key results

  • At week 24, secukinumab was associated with 86.1% of patients achieving ≥75% improvement in the Psoriasis Area and Severity Index (PASI75).
    • 68.5% of patients achieved PASI90.
    • 39.7% of patients achieved PASI100.
  • In a subgroup analysis of patients naive to systemic therapies, 92.8% achieved PASI75, 84.3% achieved PASI90, and 66.3% achieved PASI100.
  • In patients previously treated with biologics, 78.1% achieved PASI75, 54.8% achieved PASI90, and 29.0% achieved PASI100.
  • 45.9% of patients experienced an adverse event.
    • Most common were nasopharyngitis (8.7%), pruritus (2.9%), and headache (2.4%).
    • 4.1% of patients experienced a serious adverse event.
    • 6.9% of patients discontinued because of an adverse event.

Study design

  • Efficacy data for 1323 of 1988 patients from an ongoing prospective study completing 24 weeks of treatment with secukinumab for moderate to severe plaque psoriasis.
  • Of the overall cohort, 90.9% had received prior systemic therapy and 44.3% were receiving concomitant treatment.
  • Funding: Novartis Pharma GmbH.

Limitations

  • No comparator group.
  • Short study length.

References


YOU MAY ALSO LIKE